Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors

European Journal of Surgical Oncology

Volumn 40, Issue 10, 2014, Pages 1307-1312

  Ghadban, T ^a   Perez, D R ^a   Vashist, Y K ^a   Bockhorn, M ^a   Koenig, A M ^a   El Gammal, A T ^a   Izbicki, J R ^a   Metzger, U ^b   Hauswirth, F ^b   Frosina, D ^c   Jungbluth, A A ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TRIEMLI HOSPITAL   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CT10 MAGE C2; GAGE; Gastrointestinal stromal tumor; Prognosis

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN CT10; CANCER TESTIS ANTIGEN GAGE; CANCER TESTIS ANTIGEN MAGE C2; UNCLASSIFIED DRUG; MAGEC2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR VOLUME; GASTROINTESTINAL TUMOR; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS;

EID: 84925222392     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.03.011     Document Type: Article

References (34)

1. A.J. Simpson, O.L. Caballero, A. Jungbluth, Y.T. Chen, and L.J. Old Cancer/testis antigens, gametogenesis and cancer Nat Rev Cancer 5 8 2005 615 625
2. A.A. Jungbluth, W.A. Silva, and K. Iversen et al. Expression of cancer-testis (CT) antigens in placenta Cancer Immun 7 2007 15
3. O.L. Caballero, and Y.T. Chen Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Sci 100 11 2009 2014 2021
4. D. Perez, T. Herrmann, and A.A. Jungbluth et al. Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence Int J Cancer 123 7 2008 1551 1555
5. D. Perez, F. Hauswirth, and D. Jäger et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors Int J Cancer 128 12 2011 2947 2952
6. M. Luftl, G. Schuler, and A.A. Jungbluth Melanoma or not? Cancer testis antigens may help Br J Dermatol 151 6 2004 1213 1218
7. M.O. Riener, P.J. Wild, and C. Soll et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma Int J Cancer 124 2 2009 352 357
8. R. Zhuang, Y. Zhu, and L. Fang et al. Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2 Cancer Immun 6 2006 7
9. A. Curioni-Fontecedro, N. Nuber, and D. Mihic-Probst et al. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients PLoS One 6 6 2011 e21418
10. L. von Boehmer, L. Keller, and A. Mortezavi et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer PloS One 6 7 2011 e21366
11. D. Godelaine, J. Carrasco, and F. Brasseur et al. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44 Cancer Immunol Immunother 56 6 2007 753 759
12. M.F. Gjerstorff, H. Besir, M.R. Larsen, and H.J. Ditzel Expression, purification and characterization of the cancer-germline antigen GAGE12I: a candidate for cancer immunotherapy Protein Expr Purif 73 2 2010 217 222
13. R.K. Kular, F. Yehiely, and L.P. Deiss Rational drug design: a GAGE derived peptide kills tumor cells Cancer Biol Ther 9 10 2010 825 831
14. C.D. Fletcher, J.J. Berman, and C. Corless et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 5 2002 459 465
15. M. Miettinen, W. El-Rifai, H.L. Sobin L, and J. Lasota Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review Hum Pathol 33 5 2002 478 483
16. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 10 2006 1466 1478
17. J.S. Gold, M. Gönen, and A. Gutiérrez et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis Lancet Oncol 10 11 2009 1045 1052
18. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2 2006 70 83
19. V.P. Balachandran, M.J. Cavnar, and S. Zeng et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido Nat Med 17 9 2011 1094 1100
20. D.R. Perez, R.E. Baser, and M.J. Cavnar et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor Ann Surg Oncol 20 2 2013 593 599
21. R.P. Dematteo, K.V. Ballman, and C.R. Antonescu et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 9669 2009 1097 1104
22. M. Essat, and K. Cooper Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review Int J Cancer 128 9 2011 2202 2214
23. J. Li, J.F. Gong, A.W. Wu, and L. Shen Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor Eur J Surg Oncol 37 4 2011 319 324
24. H. Joensuu, M. Eriksson, and K. Sundby Hall et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 12 2012 1265 1272
25. G.D. Demetri Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors Semin Oncol 38 Suppl. 1 2011 S10 S19
26. A. Sawaki, T. Nishida, and T. Doi et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor Cancer 117 20 2011 4633 4641
27. F.F. Costa, K. Le Blanc, and B. Brodin Concise review: cancer/testis antigens, stem cells, and cancer Stem Cells 25 3 2007 707 711
28. C.L. Slingluff Jr., G.R. Petroni, and K.A. Chianese-Bullock et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting Clin Cancer Res 13 21 2007 6386 6395
29. J. Weber, J.A. Thompson, and O. Hamid et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 17 2009 5591 5598
30. F.S. Hodi, S.J. O'Day, and D.F. McDermott et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
31. J. Yuan, D.B. Page, and G.Y. Ku et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy Cancer Immun 10 2010 1
32. E. Jager, E. Stockert, and Z. Zidianakis et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events Int J Cancer 84 5 1999 506 510
33. K. Ait-Tahar, A.P. Liggins, and G.P. Collins et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma Br J Haematol 146 4 2009 396 407
34. C. Frank, M. Hundemer, A.D. Ho, H. Goldschmidt, and M. Witzens-Harig Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma Leuk Lymphoma 49 4 2008 779 785